US judge declines to intervene in fray because process ‘is creating value for Metsera stockholders’
FTC fast-tracks antitrust approval of earlier deal in sign Washington could weigh in on takeover battle with Novo Nordisk
Plus, how a little-known Utah lender became First Brands’ biggest creditor and Novo Nordisk gatecrashes Pfizer’s latest deal
Bid for drugmaker Metsera is unusually aggressive in terms of price, timing and structure
Pfizer had struck deal in September to buy obesity-focused biotech
Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of obesity medicine
Much of their time is spent appeasing and aligning competing forces
Boardroom shake-up at European drugmaker grants Lars Rebien Sørensen wide-ranging powers
Danish drugmaker grapples with slowing growth and falling share price
US administration in negotiations over cost of Danish group’s best-selling weight loss drug
Results are due soon from two studies using semaglutide to treat thousands of people with the disease
Danish drugmaker seeks to build out pipeline from mega-blockbusters Wegovy and Ozempic
Danish drugmaker is racing to beat arch-rival Eli Lilly to market
Maziar Mike Doustdar has an onerous in-tray to stop the company falling behind in the lucrative US obesity market
Danish pharma group seeks to broaden options and stay competitive with Eli Lilly
Danish drugmaker warns over slowing growth as Ozempic and Wegovy producer faces pressure from US rival Eli Lilly
Traditional intellectual property tools have proved insufficient against pharmacy compounders producing weight-loss drugs
GLP-1 medications could be the group’s death knell — or grant it a new lease on life
Federal Reserve chair is under bombardment from Trump and dealing with conflicting economic data
Danish group’s shares rise after it cuts cost for blockbuster diabetes and weight-loss drug for patients without insurance
Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise
Weight loss results come in at lower end of expectations in trial
Danish group loses share in diabetes drugs to rivals, with first-half sales growth easing to 8%
US president threatens to ‘deploy every tool in our arsenal’ to protect Americans from ‘abusive drug prices’
Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors
